UY27677A1 - Formas cristalinas de agonistas del receptor b3 adrenérgico, procedimientos para su preparación y sus usos. - Google Patents

Formas cristalinas de agonistas del receptor b3 adrenérgico, procedimientos para su preparación y sus usos.

Info

Publication number
UY27677A1
UY27677A1 UY27677A UY27677A UY27677A1 UY 27677 A1 UY27677 A1 UY 27677A1 UY 27677 A UY27677 A UY 27677A UY 27677 A UY27677 A UY 27677A UY 27677 A1 UY27677 A1 UY 27677A1
Authority
UY
Uruguay
Prior art keywords
procedures
preparation
pharmaceutical compositions
receptor agonists
adrenergic receptor
Prior art date
Application number
UY27677A
Other languages
English (en)
Inventor
Joseph F Krzyzaniak
Jennifer A Lafontaine
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27677A1 publication Critical patent/UY27677A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una forma cristalina anhidra de la sal de tosilato del (R)-2 (2- (4-axasol)-4-il-fenoxi)-etilamino)-1piridin-3-il estanol, y una forma cristalina del monohidrato de dicha sal de tosilato; procedimientos útiles para preparar dichas formas cristalinas; composiciones farmacéuticas que comprenden dichas formas cristalinas; métodos para tratar enfermedades, estados y trastornos mediados por el receptor b3- andrenérgico en un mamífero, usando dichas formas cristalinas, o dichas composiciones farmacéuticas; y métodos para aumentar el contenido de carne magra en animales comestibles usando para formar cristalinas, o dichas composiciones farmacéuticas.
UY27677A 2002-02-27 2003-02-25 Formas cristalinas de agonistas del receptor b3 adrenérgico, procedimientos para su preparación y sus usos. UY27677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36025202P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
UY27677A1 true UY27677A1 (es) 2003-10-31

Family

ID=27766208

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27677A UY27677A1 (es) 2002-02-27 2003-02-25 Formas cristalinas de agonistas del receptor b3 adrenérgico, procedimientos para su preparación y sus usos.

Country Status (8)

Country Link
US (2) US6689800B2 (es)
AU (1) AU2003209527A1 (es)
GT (1) GT200300042A (es)
PA (1) PA8567501A1 (es)
PE (1) PE20030920A1 (es)
TW (1) TW200400962A (es)
UY (1) UY27677A1 (es)
WO (1) WO2003072573A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US20050075323A1 (en) * 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
US8377465B2 (en) 2005-02-11 2013-02-19 Kansas State University Research Foundation Product and process for elevating lipid blood levels in livestock
EP4161496A1 (en) * 2020-06-04 2023-04-12 Curasen Therapeutics, Inc. Forms and compositions of a beta adrenergic agonist

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
US5051423A (en) 1988-07-13 1991-09-24 Schering Ag Derivatized alkanolamines as cardiovascular agents
US5030640A (en) 1989-01-05 1991-07-09 Merck & Co., Inc. Novel β-adrenergic agonists and pharmaceutical compositions thereof
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
ATE154935T1 (de) * 1993-06-14 1997-07-15 Pfizer Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
CN1079794C (zh) 1994-04-08 2002-02-27 住友化学工业株式会社 醚类化合物,它们的应用以及其制备中所用的中间体
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
CA2220399A1 (en) 1995-05-10 1996-11-14 Pfizer Inc. .beta.-adrenergic agonists
TR199800521T1 (xx) 1995-09-21 1998-06-22 Eli Lilly And Company Se�imli beta3 adrenerjik agonistler.
EP0882707B1 (en) 1996-01-10 2003-10-08 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
US6008361A (en) 1996-04-09 1999-12-28 Pfizer Inc. Substituted pyridines
US5859044A (en) 1996-07-31 1999-01-12 Pfizer Inc. β-adrenergic agonists
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
TR199901063T2 (xx) 1996-11-14 1999-08-23 Pfizer Inc. �kame edilmi� piridinler i�in i�lem.
US6001856A (en) 1997-06-13 1999-12-14 Pfizer Inc. β-adrenergic agonists to reduce a wasting condition
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6090942A (en) 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
DE60015036T2 (de) 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
US6451587B1 (en) 1999-09-29 2002-09-17 Pfizer Inc. Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
BR0114836A (pt) * 2000-10-20 2003-07-01 Pfizer Prod Inc Agonistas de receptores beta-3 adrenérgicos e suas aplicações
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
EP1236723A1 (en) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol

Also Published As

Publication number Publication date
US20030199556A1 (en) 2003-10-23
AU2003209527A1 (en) 2003-09-09
PE20030920A1 (es) 2003-10-29
GT200300042A (es) 2003-09-22
PA8567501A1 (es) 2003-11-12
US20030166686A1 (en) 2003-09-04
TW200400962A (en) 2004-01-16
US6689800B2 (en) 2004-02-10
WO2003072573A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
AR056055A1 (es) Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno
AR062536A1 (es) Acilanilidas sustituidas y composicion farmaceutica
PA8800701A1 (es) Sales de maleato de [e]-n-{4-[3-cloro-4-[2-piridinilmetoxi]anilino]-3-ciano-7-etoxi-6-quinolinil}-4-[dimetilamino]-2-butenamide, sus formas cristalinas, procesos para su preparacion, y metodos para su uso
SV2011003842A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CL2007003187A1 (es) Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
BRPI0817693A2 (pt) Métodos e aparelho para iluminar ovos atráves de detecção de batimento cardíaco do embrião
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
AR057222A1 (es) Agonistas del receptor del neuropeprtido -2
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
AR054252A1 (es) Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
GT200500309A (es) Derivados de sulfonilbencilimidazol
UY29790A1 (es) Sales de diariloimidazola-4-carboxamidas, composiciones que las contienen, procesos de preparación y aplicaciones
AR076519A1 (es) Coaglomerados de manitol y de almidon granular comprimibles y de libre fluidez. procedimiento de preparacion.
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
AR065519A1 (es) Sales de adicion de acido, hidratos y polimorfos de la etil - amida del acido 5- (2,4- dihidroxi -5- isopropil - fenil )-4-(4- morfolin-4-il-metil - fenil ) - isoxasol-3- carboxilico y formulaciones que comprenden estas formas
CL2011001258A1 (es) Sales de adicion de acido citrico de (r)-5-((e)-2-pirrolidin-3-il vinil)pirimidina; formas polimorficas monocitrato; composicion farmaceutica que las comprende; y su uso en la prevencion o en el tratamiento del dolor, inflamacion o un trastorno del sistema nervioso central.
UY27677A1 (es) Formas cristalinas de agonistas del receptor b3 adrenérgico, procedimientos para su preparación y sus usos.
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
DOP2003000591A (es) Formas cristalinas de agonistas del receptor b3-adrenergico, procedimiento para su preparacion, y sus usos
PE20040176A1 (es) Ambroxol para el tratamiento de dolores cronicos
DOP2003000592A (es) Sal agonista del receptor b3 adrenergico, sus formulaciones y usos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126